Stocks and Investing
Stocks and Investing
Thu, June 13, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Hartaj Singh Maintained (SPRB) at Buy with Decreased Target to $3 on, Jun 13th, 2024
Hartaj Singh of Oppenheimer, Maintained "Spruce Biosciences, Inc." (SPRB) at Buy with Decreased Target from $4 to $3 on, Jun 13th, 2024.
Hartaj has made no other calls on SPRB in the last 4 months.
There are 6 other peers that have a rating on SPRB. Out of the 6 peers that are also analyzing SPRB, 5 agree with Hartaj's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Hold on, Wednesday, June 5th, 2024
- Aydin Huseynov of "Ladenburg Thalmann" Downgraded from Strong Buy to Hold on, Thursday, March 14th, 2024
- Evan Wang of "Guggenheim" Downgraded from Strong Buy to Hold on, Thursday, March 14th, 2024
- Gregory Renza of "RBC Capital" Downgraded from Buy to Hold and Decreased Target to $2 on, Thursday, March 14th, 2024
- Joseph Schwartz of "Leerink Partners" Downgraded from Buy to Hold and Decreased Target to $2 on, Thursday, March 14th, 2024
This is the rating of the analyst that currently disagrees with Hartaj
- Jonathan Wolleben of "JMP Securities" Maintained at Buy with Decreased Target to $3 on, Thursday, March 14th, 2024
Contributing Sources